ID

7555

Description

SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Link

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Keywords

Clinical Trial

Off-Treatment

Breast Neoplasms

8/26/12 8/26/12 -
1/9/15 1/9/15 - Martin Dugas

Uploaded on

January 9, 2015

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00127205 Off Treatment - SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) - 2287059v3.0

Details

No Instruction available.

1 forms

StudyEvent: SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307)
1. No Instruction available.

Header

SWOG Patient ID

SWOG Study No.

Registration Step

Patient Initials (L, F M)

Institution/Affiliate

Physician

Participating Group Name

Participating Group Study No.

Participating Group Patient ID (Instructions: Submit this form after completion of end-of-study bone scan. If bone scan was not done, explain in Comments. All dates are MONTH, DAY, YEAR. Explain any blank fields or blank dates in the Comments section. Place an X in appropriate boxes. Circle AMENDED items in red and write AMENDED across top of form.)

Bone Scan

Did the patient have a bone scan after completion or discontinuation of protocol therapy?

Yes

date of bone scan (If yes,)

Bone metastases?

Yes

Patient Preference

If oral and intravenous bisphosphonates are equally effective in preventing breast cancer recurrence in the bone, which would the patient prefer to receive?

Oral (Oral)

Intravenous (Intravenous)

Comments

Back to the top of the page

Similar models

Show recommended models

ID